Jasper Therapeutics’ (JSPR) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report sent to investors on Monday,Benzinga reports. They currently have a $68.00 price target on the stock.

Other analysts have also issued reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. JMP Securities restated a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a report on Tuesday, October 15th. HC Wainwright reiterated a “buy” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a report on Thursday, October 24th. Evercore ISI restated an “outperform” rating and set a $65.00 price target on shares of Jasper Therapeutics in a research note on Monday, August 26th. Finally, BMO Capital Markets started coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective on the stock. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $73.38.

Jasper Therapeutics Trading Down 1.9 %

NASDAQ:JSPR opened at $21.71 on Monday. Jasper Therapeutics has a 12 month low of $5.02 and a 12 month high of $31.01. The stock has a market capitalization of $325.67 million, a price-to-earnings ratio of -4.58 and a beta of 2.18. The firm has a fifty day simple moving average of $21.88 and a two-hundred day simple moving average of $20.66.

Institutional Trading of Jasper Therapeutics

Institutional investors have recently made changes to their positions in the company. Samsara BioCapital LLC boosted its holdings in Jasper Therapeutics by 11.4% during the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after purchasing an additional 59,642 shares during the last quarter. Ally Bridge Group NY LLC lifted its position in shares of Jasper Therapeutics by 82.7% during the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after buying an additional 180,852 shares in the last quarter. Braidwell LP purchased a new position in shares of Jasper Therapeutics in the 3rd quarter worth approximately $9,091,000. FMR LLC bought a new position in shares of Jasper Therapeutics in the third quarter valued at approximately $722,000. Finally, Wellington Management Group LLP bought a new position in shares of Jasper Therapeutics in the third quarter valued at approximately $447,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.